Enterogenic dementia: defining the gut-brain axis and the role of inflammatory bowel disease in cognitive impairment.

IF 5.3 2区医学 Q2 IMMUNOLOGY

Inflammopharmacology Pub Date : 2025-09-30 DOI:10.1007/s10787-025-01940-6

Faisal Alshammari, Hayder M Al-Kuraishy, Mustafa M Shokr, Marios Papadakis, Athanasios Alexiou, Gaber El-Saber Batiha

引用次数: 0

Abstract

Dementia is a clinical syndrome due to brain neurodegeneration and associated oxidative stress and neuroinflammation. Chronic inflammatory and immunological diseases are associated with the development of dementia due to the development of neuroinflammation and synaptic dysfunction. Dementia is commonly related to inflammatory bowel disease (IBD), which may be named as an enterogenic dementia, which results from gut dysbiosis, systemic inflammation, and neuroinflammation. IBD is regarded as a potential risk factor for the development and progression of dementia, known as enterogenic dementia, through different mechanisms such as alteration of the gut-brain axis and gut dysbiosis. However, the precise mechanism linking IBD and dementia is not fully elucidated and remains elusive. In this perspective, we try to discuss the mechanisms for the development and progression of enterogenic dementia in relation to IBD and gut dysbiosis.

查看原文本刊更多论文

肠源性痴呆：定义肠脑轴和炎症性肠病在认知障碍中的作用

痴呆症是一种临床综合征，由于脑神经变性和相关的氧化应激和神经炎症。由于神经炎症和突触功能障碍的发展，慢性炎症性和免疫性疾病与痴呆的发展有关。痴呆症通常与炎症性肠病（IBD）有关，IBD可能被称为肠源性痴呆，由肠道生态失调、全身炎症和神经炎症引起。IBD被认为是痴呆发生和发展的潜在危险因素，被称为肠源性痴呆，通过不同的机制，如肠脑轴的改变和肠道生态失调。然而，IBD和痴呆之间的确切机制尚未完全阐明，仍然难以捉摸。从这个角度来看，我们试图讨论与IBD和肠道生态失调相关的肠源性痴呆的发生和进展机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Inflammopharmacology IMMUNOLOGYTOXICOLOGY-TOXICOLOGY

CiteScore

8.00

自引率

3.40%

发文量

200

期刊介绍： Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn''s disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas: -Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states -Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs -Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents -Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain -Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs -Muscle-immune interactions during inflammation [...]